Impaired angiogenic response in the cornea of mice lacking tenascin C

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 5, 2011, Pages 2462-2467

  Sumioka, Takayoshi ^a   Fujita, Norihito ^a   Kitano, Ai ^a   Okada, Yuka ^a   Saika, Shizuya ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TENASCIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAUTERIZATION; CELL CULTURE; CELL INVASION; CONTROLLED STUDY; CORNEA; CORNEA NEOVASCULARIZATION; CORNEA STROMA; FIBROBLAST; FIBROBLAST CULTURE; GENE EXPRESSION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; KNOCKOUT MOUSE; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; CELLS, CULTURED; CORNEAL NEOVASCULARIZATION; CORNEAL STROMA; DISEASE MODELS, ANIMAL; FIBROBLASTS; GENE EXPRESSION REGULATION; IMMUNOENZYME TECHNIQUES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TENASCIN; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955991074     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5750     Document Type: Article

References (33)

1. Brodovsky SC, McCarty CA, Snibson G, et al. Management of alkali burns: an 11-year retrospective review. Ophthalmology. 2000;107: 1829-1835.
2. Meller D, Pires RT, Mack RJ, et al. Amniotic membrane transplantation for acute chemical or thermal burns. Ophthalmology. 2000; 107:980-989.
3. Saika S, Ikeda K, Yamanaka O, et al. Expression of Smad7 in mouse eyes accelerates healing of corneal tissue after exposure to alkali. Am J Pathol. 2005;166:1405-1418.
4. Saika S, Miyamoto T, Yamanaka O, et al. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factorkappaB, in treatment of corneal alkali burns in mice. Am J Pathol. 2005;166:1393-1403.
5. Saika S, Yamanaka O, Sumioka T, et al. Fibrotic disorders in the eye: targets of gene therapy. Prog Retin Eye Res. 2008;27:177-196.
6. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264-302.
7. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008;145:424-431.
8. Saika S. TGFb pathobiology in the eye. Lab Invest. 2006;86:106-115.
9. Fujita S, Saika S, Kao WW, et al. Endogenous TNFalpha suppression of neovascularization in corneal stroma in mice. Invest Ophthalmol Vis Sci. 2007;48:3051-3055.
10. Francis ME, Uriel S, Brey EM. Endothelial cell-matrix interactions in neovascularization. Tissue Eng Part B Rev. 2008;14:19-32.
11. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal. 2009 Oct 17. [Epub ahead of print.]
12. Shrestha P, Sakamoto F, Takagi H, et al. Enhanced tenascin immunoreactivity in leukoplakia and squamous cell carcinoma of the oral cavity: an immunohistochemical study. Eur J Cancer B Oral Oncol. 1994;30:132-137.
13. Ballard VL, Sharma A, Duignan I, et al. Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. FASEB J. 2006;20:717-719.
14. Ishiwata T, Takahashi K, Shimanuki Y, et al. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res. 2005;25:489-495.
15. Saito Y, Shiota Y, Nishisaka M, et al. Inhibition of angiogenesis by a tenascin-c peptide which is capable of activating beta1-integrins. Biol Pharm Bull. 2008;31:1003-1007.
16. Wallner K, Li C, Shah PK, et al. Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation. 1999;99:1284-1289.
17. Ljubimov AV, Saghizadeh M, Pytela R, et al. Increased expression of tenascin-C-binding epithelial integrins in human bullous keratopathy corneas. J Histochem Cytochem. 2001;49:1341-1350.
18. Wachtlin J, Langenbeck K, Schründer S, et al. Immunohistology of corneal wound healing after photorefractive keratectomy and laser in situ keratomileusis. J Refract Surg. 1999;15:451-458.
19. Akhtar S, Bron AJ, Hawksworth NR, et al. Ultrastructural morphology and expression of proteoglycans, betaig-h3, tenascin-C, fibrillin-1, and fibronectin in bullous keratopathy. Br J Ophthalmol. 2001;85:720-731.
20. Matsuda A, Yoshiki A, Tagawa Y, et al. Corneal wound healing in tenascin knockout mouse. Invest Ophthalmol Vis Sci. 1999;40: 1071-1080.
21. Herold-Mende C, Mueller MM, Bonsanto MM, et al. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer. 2002;20:362-369.
22. Hirata E, Arakawa Y, Shirahata M, et al. Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue. Cancer Sci. 2009;100:1451-1459.
23. Saika S, Ikeda K, Yamanaka O, et al. Loss of tumor necrosis factor a potentiates transforming growth factor b-mediated pathogenic tissue response during wound healing. Am J Pathol. 2006;168: 1848-1860.
24. Cambridge GW, Parsons JF, Friend JV, et al. Some effects of lignocaine on cultured mouse peritoneal macrophages. Agents Actions. 1985;16:548-551.
25. Kitano A, Saika S, Yamanaka O, et al. Emodin suppression of ocular surface inflammatory reaction. Invest Ophthalmol Vis Sci. 2007; 48:5013-5022.
26. Goh FG, Piccinini AM, Krausgruber T, et al. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J Immunol. 2010;184:2655-2662.
27. Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. 2009;15: 774-780.
28. Kulla A, Liigant A, Piirsoo A, et al. Tenascin expression patterns and cells of monocyte lineage: relationship in human gliomas. Mod Pathol. 2000;13:56-67.
29. Naldini A, Leali D, Pucci A, et al. Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol. 2006;177:4267-4270.
30. Behrem S, Zarković K, Eskinja N, et al. Distribution pattern of tenascin-C in glioblastoma: correlation with angiogenesis and tumor cell proliferation. Pathol Oncol Res. 2005;11:229-235.
31. Sato T, Nakai T, Tamura N, et al. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut. 2005; 54:1254-1262.
32. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, et al. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol. 2005;167:71-80.
33. Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. 2009;15: 774-780.